Table 2.
Response per first-line treatment.
| Temozolomide n = 32 (%) |
Ipilimumab n = 24 (%) |
Pembrolizumab n = 43 (%) |
Ipilimumab/Nivolumab n = 19 (%) |
|
|---|---|---|---|---|
| CR | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| PR | 0 (0%) | 0 (0%) | 3 (7.0%) | 4 (21.1%) |
| SD ≥ 24 weeks | 2 (6.3%) | 6 (25.0%) | 12 (27.9%) | 2 (10.5%) |
| PD | 30 (93.4%) | 18 (75.0%) | 28 (65.1%) | 13 (68.4%) |
| PFS, median | 2.5 | 3.0 | 4.8 | 3.7 |
| 6-month PFS rate | 3.1% | 16.7% | 32.6% | 31.6% |
| OS, median | 5.7 | 9.9 | 10.3 | 18.9 |
| 1-year OS rate | 18.8% | 50.0% | 38.7% | 57.6% |
CR, complete response; OS, overall survival (in months); PD, progressive disease; PFS, progression-free survival (in months); PR, partial response; SD, stable disease.